MedCity News April 21, 2024
As cell and gene therapies continue to make headlines as a key opportunity for growth, success in this field will require both innovative tech as well as strategic foresight.
In recent years cell and gene therapies have taken the main stage in biotech as they promise to address a broad array of indications and patient populations that have historically had significantly unmet needs. Even in the face of an investment downturn, the cell and gene therapy industry saw $11.7B in investments in 2023. Building on these current trends and wins, McKinsey has highlighted the cell and gene therapy industry as a key opportunity that will continue to draw strong investor interest.
With over 2500 existing developers worldwide, and more...
Today's Sponsors
Today's Sponsor